Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (May 2025)
29 slides from Glaukos's investor presentation, May 2025

Slide 1: Investor Presentation May 2025
Investor Presentation May 2025

Slide 2: Disclaimer
Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current e

Slide 3: We'll Go Leading-edge First: Core Growth Strategy
WE’LL GO Leading-edge CORE GROWTH STRATEGY Dropless Commercial Innovation Therapies Excellence FIRST Pursuing big ideas that address clinical needs of large and/or underserved patient populations Challenging conventional paradigms to advance the standards of care and improve outcomes Building durabl

Slide 4: Industry-Leading Innovation
Ocular Hypertension and INDUSTRY- Open-Angle Glaucoma LEADING INNOVATION 700 $ + Million Invested in R&D since 2018 AMD 14 DME RVO Disclosed pipeline Blepharitis Keratoconus Presbyopia programs in 2025 vs. Glaucoma 4 in 2015 Dry Eye © 2025 Glaukos Corporation 4

Slide 5: 2025-26 Key Commercial Catalysts
2025-26 KEY COMMERCIAL Interventional CATALYSTS Glaucoma iDose® TR iStent infinite® Focused on establishing robust growth engines centered on proven, Keratoconus foundational therapies iLinko2n with EpioxaTM that improve the standard of care iLinko2n with Epioxa is not approved by the FDA © 2025 Gla

Slide 6: Disrupting the Status Quo
DISRUPTING DROPS = POOR PATIENT COMPLIANCE & REDUCED QUALITY OF LIFE 90 50 Topical meds remain the dominant glaucoma treatment but… Complex dosing regimens, instillation difficulties and THE STATUS % % chronic side effects are common problems > ~ QUO & of patients are non- of patients purposely disc

Slide 7: IG: Led by iDose TR, Groundbreaking Innovation
IG: LED BY iDOSE TR, iDose TR is designed to provide 24/7, continuous, long-duration drug therapy to address ubiquitous patient non-compliance with topical GROUND- medications BREAKING <0.5mm INNOVATION 1.8mm Unique Drug Formulation 75 mcg of a novel, proprietary, preservative-free travoprost formul

Slide 8: IG: A New Paradigm
IG: A NEW PARADIGM The workhorse; foundational therapy in algorithms across the disease stage spectrum SLT Designed to provide 24/7 long-duration sustained release of travoprost directly into the anterior chamber; for full range of disease progression where goal is to reduce IOP OR DRUG DELIVERY OCU

Slide 9: Driving IG Forward
DRIVING IG Further broaden market access among MACs, FORWARD Methodical launch; continually commercial and Medicare Advantage (MA) payors Eight journal expanded trained surgeon pool articles published Accelerate marketing investments as Permanent universe of trained surgeons grows J-Code Cat III CPT

Slide 10: IG & The Forever Patient
IG & THE COMPREHENSIVE OPHTHALMOLOGY PRACTICE: CONVENTIONAL MODEL Optimizing referral network and Glaucoma care predominantly single Patients can be lost to follow-up and FOREVER practice administration for cataract and refractive care treatment per patient, then referred back to OD or glaucoma spec

Slide 11: Strong IG Clinical Data
STRONG IG CLINICAL DATA iDose TR: Phase 3 data confirms long duration 81 % OF iDOSE TR SUBJECTS WELL-CONTROLLED ON THE % PATIENTS WELL CONTROLLED ON THE SAME OR FEWER SAME OR FEWER IOP-LOWERING TOPICAL MEDICATIONS TOPICAL IOP-LOWERING MEDS IN PHASE 3 TRIAL AT 3 YEARS3 % AT 12 MONTHS AT 36 MONTHS 70%

Slide 12: Strong IG Safety Data
STRONG IG iDose TR: Phase 3 & Phase 2b safety data SAFETY DATA Ph 3 Trials Ph 2b Trial Topical PGAs2 3 Years 3 Years No adverse events of periorbital fat Up to 70% incidence atrophy In controlled studies, the most common ocular Very low conjunctival hyperemia 30%-50% incidence adverse reactions in 2

Slide 13: Power of Combined Therapy
POWER OF ≥3 Meds NUMBER OF MEDICATIONS BY % OF PATIENTS (US)1 COMBINING THERAPIES COMBINED 24% 1 Med Combining multiple topical meds is widely used to Combinatorial therapy has potential to better control IOP with different mechanisms of action 48% THERAPY manage IOP by increasing 2 Meds outflow and

Slide 14: Estimating the Domestic IG Opportunity
ESTIMATING THE INTERVENTIONAL GLAUCOMA1 DOMESTIC IG MIGS + CATARACT 22M 13M 12M OPPORTUNITY 0.5M eyes eyes eyes eyes Annual Procedures Diagnosed & Diagnosed Treated Prevalence Are non-compliant and/or Have physical limitations intolerant with topical meds that impede their ability to use topical med

Slide 15: IG Product Roadmap
IG PRODUCT ROADMAP PRODUCT PATIENT STATUS iStent / iStent inject / iStent Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) inject W iStent infinite Glaucoma (failed on prior therapy) FDA Cleared (2022) iStent infinite Glaucoma (label expansion) Active PMA Study PRESERFLO Micro

Slide 16: IG: A Vision for the Next 10 Years
IG: A VISION FOR THE NEXT 6 5 A new breed of IG specialist could emerge, conducting primarily injection therapy while vertically integrated ODs and 10 YEARS OD referral networks provide preparatory patient services 4 PE groups are likely to gravitate to IG therapy due to the significant clinical ben

Slide 17: Advances in Corneal Health
RARE DISEASE: KEY KERATOCONUS (KC) FACTS ADVANCES IN • A type of corneal ectasia characterized by corneal thinning CORNEAL and steepening; often marked by frequent eye rubbing Photrexa (Epi-off) is the first and only HEALTH • Most cases present between puberty and age 40 • Patients may require multi

Slide 18: Epioxa (Epi-on) Next-Gen Therapy Moves Forward
EPIOXA (Epi-on) NEXT-GEN Oxygen-enriched epithelium-on corneal THERAPY cross-linking designed to: MOVES Retain corneal epithelium Streamline procedure FORWARD Improve patient comfort Shorten recovery time EPIOXA PHASE 3 OUTCOMES Perfused oxygen is key to improved Supplemental oxygen is critical for

Slide 19: Customized, Spherical Therapy
WHAT IF? CUSTOMIZED, THIRD-GENERATION iLINK THERAPY DESIGNED TO: • Use biomechanical modeling to SPHERICAL deliver customized, patterned treatment that matches each THERAPY patient’s unique corneal topography • Use proprietary algorithm to precisely target UV energy for Third-generation iLink therap

Slide 20: iLink / KC Product Roadmap
iLINK / KC PRODUCT ROADMAP PRODUCT PATIENT STATUS Photrexa (Epi-off) Keratoconus FDA Approved (2016) NDA filed Epioxa (Epi-on) Keratoconus PDUFA date: 10/20/25 iLink 3rd Generation Keratoconus Phase 2 Robust pipeline is designed to expand and enhance patient care options with iVeena (IVMED-80) Kerat

Slide 21: iLution Platform Update
iLUTION POTENTIAL BENEFITS OF EYELID DELIVERY VS PRESCRIPTION EYE DROPS • Easier administration • Fewer side effects PLATFORM • Faster onset of action • Better compliance UPDATE DEMODEX BLEPHARITIS iLUTION DEMODEX BLEPHARITIS PROGRAM • Affects an estimated 25 million1 people in the US Transdermal dr

Slide 22: Retina XR Platform Update
RETINA XR Conventional intravitreal 39 Monthly or bi-monthly anti-VEGF injections are standard PLATFORM of care for AMD, DME and RVO but studies show that injections impose tremendous % treatment burdens on patients UPDATE and contribute to lack of Are lost to follow- 28 compliance up within 2 years

Slide 23: Building the Business in Stages
BUILDING THE BUSINESS IN BUILDING THE iStent & Other Surgical iDose iLink iLution Retina STAGES BUSINESS IN iStent/iStent inject* iDose TR iLution TR iDose TREX Stage 1: iStent inject W* STAGES iStent infinite iDose Gen 3 INTERVENTIONAL PreserFlo GLAUCOMA iAccess 2012 Radius IOP Sensor Stage 2: Ph

Slide 24: Among Industry's Most Formidable Glaucoma and Cornea Portfolios
AMONG PRODUCT iStent / iStent inject / iStent inject W PATIENT Mild-to-Moderate Glaucoma with Cataract STATUS FDA Approved (2012, 2018, 2020) INDUSTRY’S iStent infinite Glaucoma (failed on prior therapy) FDA Cleared (2022) iStent infinite Glaucoma (label expansion) Active PMA Study GLAUCOMA MOST PRE

Slide 25: Key 2025 Pipeline Milestones
KEY 2025 PROGRAM PATIENT INTENDED CLINICAL BENEFIT 2025 MILESTONE TARGET GLAUCOMA Mild-to-Moderate PIPELINE MIGS therapy Advance enrollment in PMA pivotal trial Glaucoma iStent infinite Advanced-Refractory MIGS therapy EU regulatory approval MILESTONES Glaucoma Advanced-Refractory PRESERFLO MicroShu

Slide 26: Building the Business in Key Highlights
BUILDING THE BUSINESS IN 82 NET SALES1 GLOBAL INFRASTRUCTURE GROSS MARGIN2 17 (in millions) (1Q 2025) KEY STAGES $480 Countries with % $383 20%+ HIGHLIGHTS $315 10-year direct operations 300+ CAGR $283 Global commercial 2022 personnel 2023 2024 2025 SPECIALIZED MANUFACTURING SALES MIX HEALTHY BALANC

Slide 27: We'll Go First
WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases. © 2025 Glaukos Corporation 27

Slide 28: © 2025 Glaukos Corporation 28
© 2025 Glaukos Corporation 28

Slide 29: Appendix: GAAP to Non-GAAP Reconciliation 1Q 2025
Appendix GAAP to Non-GAAP Reconciliation - 1Q 2025 (in thousands) 1Q 2025 GAAP Amort. of Dev 1Q 2025 Non-GAAP Gross Margin Tech Intangibles Gross Margin Net Sales $ 106,664 $ 106,664 COGS $ 24,316 $ (5,523) $ 18,793 Gross Profit $ 82,348 $ 5,523 $ 87,871 Gross Margin 77% 82% © 2025 Glaukos Corporati
Source: Internet Archive copy of s206.q4cdn.com
More decks from Glaukos Corporation
Investor Presentation (November 2026)29 slides · Nov 6, 2026
Q3 2026 Earnings Presentation7 slides · Oct 28, 2026
Investor Presentation (August 2026)28 slides · Aug 3, 2026
Q2 2026 Earnings Presentation27 slides · Jul 29, 2026
Q2 2026 Earnings Presentation28 slides · Jul 29, 2026
Investor Presentation (May 2026)28 slides · May 4, 2026